Liraglutide Saxenda Active substance LiraglutideDomain Metabolism and EndocrinologyReason of inclusion in Horizonscan Geneesmiddelen Indication extensionMain indication Other metabolism and EndocrinologyExtended indication Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescent patients from the age of 12 years and above with body weight above 60 kg and obesity (BMI corresponding to ≥30 kg/m2 for adults). 1. Product Proprietary name SaxendaManufacturer Novo NordiskMechanism of action GLP-1 receptor agonistRoute of administration SubcutaneousTherapeutical formulation InjectionBudgetting framework Extramural (GVS)Additional comments GLP-1 analoog 2. Registration Registration route Centralised (EMA)Type of trajectory Normal trajectorySubmission date February 2020Expected Registration January 2021Orphan drug NoRegistration phase Registration application pending 3. Therapeutic value Therapeutic value No judgementDuration of treatment Not foundFrequency of administration 1 times a dayReferences NCT02918279 4. Expected patient volume per year There is currently nothing known about the expected patient volume. 5. Expected cost per patient per year There is currently nothing known about the expected cost. 6. Potential total cost per year There is currently nothing known about the possible total cost. 7. Off label use There is currently nothing known about off label use. 8. Indication extension There is currently nothing known about indication extensions. 9. Other information There is currently no futher information available.